Programs Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response : SCARDA

Outline

Based on the national strategy, Strategy for Strengthening the Vaccine Development and Production System, the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) was established at AMED in March 2022 to strengthen strategic research funding and to promote the formation of world-class research and development centers. We prepare for future infectious disease emergencies and will respond to more virulent mutant strains and infectious diseases that could be a threat in the future.

Organization & Management

  • Director General, HAMAGUCHI Michinari, M.D., Ph.D.
  • Provost, KOGA Junichi, Ph.D.

Department of Advanced Vaccine Research and Development

Division of Vaccine Research and Development Strategy

The Division of Vaccine Research and Development Strategy collects and analyzes wide-ranging information on vaccine development that will lead to strategically significant research funding, and simultaneously attempts management involving a comprehensive overview of the state of progress of the program, “Strengthening Program for Pharmaceutical Startup Ecosystem” and the overall state of domestic vaccine development and commercialization.

Division for Promotion of Vaccine Research and Development

The Division for Promotion of Vaccine Research and Development promotes the two programs, “Program on R&D of New Generation Vaccine including New Modality Application” and “Japan Initiative for World-leading Vaccine Research and Development Centers”, and implements the appropriate management of those projects adopted.

Programs

Program on R&D of new generation vaccine including new modality application

With regard to the prioritized infectious diseases stipulated by the government, we aims to provide in Japan and overseas safe and efficient vaccines that can make an international contribution in the event of an infectious disease emergency at the earliest possible juncture. Accordingly, in anticipation of an infectious disease emergency, support is provided for (i) infectious disease vaccine development and (ii) research and development into new modalities contributing to vaccine development through integrated and flexible allocation of budgets.

Japan Initiative for World-leading Vaccine Research and Development Centers

Aiming for the achievement of Japanese-made vaccines, world-leading research and development centers (a flagships center, centers promising synergetic effects, support institutions) are set up. At these research centers, we strengthen and promote vaccine-related research aiming to achieve practical results during normal times.

Last updated 12/25/23